Claims for Patent: 8,445,190

Summary for Patent: 8,445,190

Title:	Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
Abstract:	Methods for reducing or eliminating biomaterial-induced procoagulant activity in blood subjected to extracorporeal treatment that exposes the blood to the biomaterial are disclosed. The methods involve treatment of the blood, or the extracorporeal biomaterial, or both, with a complement inhibitor to inhibit C5a/C5aR-mediated tissue factor formation in the blood.
Inventor(s):	Lambris; John D. (Philadelphia, PA), Ritis; Konstantinos (Alexandroupolis, GR)
Assignee:	The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:	13/121,396
Patent Claims:	1. A method for reducing or eliminating biomaterial-induced procoagulant activity in blood subjected to extracorporeal treatment that exposes the blood to the biomaterial, the method comprising treating the blood, or the biomaterial, or both, with a complement inhibitor in an amount effective to reduce or prevent C5a/C5aR-mediated tissue factor (TF) formation, thereby reducing or eliminating the biomaterial-induced procoagulant activity in the blood. 2. The method of claim 1, wherein the complement inhibitor comprises one or more of a C5a inhibitor, a C5aR inhibitor, a C3 inhibitor, a factor D inhibitor, a factor B inhibitor, a C4 inhibitor, a C1q inhibitor, or any combination thereof. 3. The method of claim 2, wherein the complement inhibitor is a C5a inhibitor or a C5aR inhibitor. 4. The method of claim 3, wherein the C5a inhibitor or C5aR inhibitor is acetyl-Phe-[Orn-Pro-D-cyclohexylalanine-Trp-Arg] (PMX-53), PMX-53 analogs, neutrazumab, TNX-558, eculizumab, pexelizumab or ARC1905, or any combination thereof. 5. The method of claim 2, wherein the complement inhibitor is a C3 inhibitor. 6. The method of claim 5, wherein the C3 inhibitor is compstatin, a compstatin analog, a compstatin peptidomimetic, a compstatin derivative, or any combinations thereof. 7. The method of claim 2, wherein the complement inhibitor is a C4 inhibitor. 8. The method of claim 1 wherein the extracorporeal treatment of blood comprises hemodialysis. 9. The method of claim 8, wherein the biomaterial comprises hemodialysis filter fibers. 10. The method of claim 8, wherein the blood is from an individual with renal disease. 11. The method of claim 10, wherein the renal disease is end stage renal disease (ESDR). 12. The method of claim 1, wherein the blood is contacted with the complement inhibitor prior to and/or during the extracorporeal treatment. 13. The method of claim 1, wherein the biomaterial is contacted with the complement inhibitor prior to the extracorporeal treatment. 14. The method of claim 1, wherein the complement inhibitor treatment is used together or concurrently with, or sequentially before or after, at least one other anti-coagulant or anti-inflammatory treatment of the blood. 15. A kit comprising a complement inhibitor and a biomaterial for use in an extracorporeal treatment device, and, optionally, instructions for using the complement inhibitor in a method such as the one described above. 16. The kit of claim 15, comprising hemodialysis filtration fibers. 17. An extracorporeal treatment device that includes a complement inhibitor-treated biomaterial, or a biomaterial adapted for or amenable to treatment with a complement inhibitor. 18. The device of claim 17, which is a hemodialysis unit.

Details for Patent 8,445,190

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Alexion Pharmaceuticals, Inc.	SOLIRIS	eculizumab	Injection	125166	03/16/2007		2039-02-26